Shire's Fosrenol Marketing Campaign Will Follow Adderall Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Detailing efforts for the end-stage renal disease therapy will focus on the top-prescribing nephrologists and dieticians, Shire CEO Emmens says. Company will highlight Fosrenol's high selectivity and potency to differentiate the product from Genzyme's Renagel.